Teva Pharmaceuticals
TEVA
876 hedge funds and large institutions have $40B invested in Teva Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 135 funds opening new positions, 290 increasing their positions, 310 reducing their positions, and 69 closing their positions.
96% more first-time investments, than exits
New positions opened: 135 | Existing positions closed: 69
79% more call options, than puts
Call options by funds: $1.18B | Put options by funds: $662M
50% more funds holding in top 10
Funds holding in top 10: 58 → 87 (+29)
34% more capital invested
Capital invested by funds: $29.9B → $40B (+$10.1B)
6% more funds holding
Funds holding: 823 → 876 (+53)
4.84% more ownership
Funds ownership: 55.28% → 60.12% (+4.8%)
6% less repeat investments, than reductions
Existing positions increased: 290 | Existing positions reduced: 310
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$999M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$771M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$474M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$372M |
| 5 |
IC
Institutional Capital
Chicago,
Illinois
|
+$270M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$430M |
| 2 |
MIP
Mondrian Investment Partners
London,
United Kingdom
|
-$244M |
| 3 |
Renaissance Technologies
New York
|
-$145M |
| 4 |
NTC
North Tide Capital
Boston,
Massachusetts
|
-$105M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$99.7M |
TEVA Hedge Fund Activity: Q4 2015 in Review
876 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q4 2015, worth a combined $40B — up 34% from $29.9B a quarter earlier.
Buyers outnumbered sellers: 135 funds opened new TEVA positions and 69 closed out — a net gain of 66 holders — while 290 added to existing stakes and 310 trimmed.
The largest buyer was Viking Global Investors, adding an estimated $999M. The largest seller was Franklin Resources, cutting an estimated $430M.
- 876 institutional investors held Teva Pharmaceuticals (TEVA) as of Q4 2015, up from 823 in Q3 2015.
- Funds reported $40B of Teva Pharmaceuticals stock for Q4 2015, up 34% quarter-over-quarter.
- 135 funds opened new Teva Pharmaceuticals positions in Q4 2015 and 69 closed out, a net change of +66 holders.
- The largest Teva Pharmaceuticals buyer in Q4 2015 was Viking Global Investors, an estimated $999M added.
- The largest Teva Pharmaceuticals seller in Q4 2015 was Franklin Resources, an estimated $430M sold.
Based on aggregated 13F filings for Q4 2015.